| Literature DB >> 15527511 |
Matilde De Simone1, Ugo Cioffi, Ettore Contessini-Avesani, Barbara Oreggia, Roberta Paliotti, Alberto Pierini, Gianni Bolla, Elide Oggiano, Stefano Ferrero, Fabio Magrini, Michele M Ciulla.
Abstract
BACKGROUND: In the hypothesis that the increased collagen metabolism in the intestinal wall of patients affected by inflammatory bowel disease (IBD) is reflected in the systemic circulation, we aimed the study to evaluate serum level of procollagen III peptide (PIIIP) in peripheral and splanchnic circulation by a commercial radioimmunoassay of patients with different histories of disease.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15527511 PMCID: PMC543466 DOI: 10.1186/1471-230X-4-29
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Figure 1Histological images obtained from two IBD patients enrolled in the study affected by CD (panel a) and UC (panel b) with 12.0 and 10.3 μg/l splanchnic levels of PIIIP, respectively. Panel a, CD: in the transmural section is clearly evident an ulceration (o) in the mucosa and submucosa with diffuse inflammatory infiltrations, pseudo-follicle nodules (arrow), and fibrosis of the intestinal wall. Panel b, UC: the inflammatory infiltration is more evident in the mucosa and submucosa with criptic abscesses (asterisks). A serpiginous linear ulcer is evident (arrow).
Clinical aspects of the studied patients
| 1 | 34 | F | 12 | Severe | |
| 2 | 35 | M | 8 | Moderate | |
| 3 | 38 | M | 15 | Severe | |
| 4 | 32 | F | 8 | Severe | |
| 5 | 43 | F | 14 | Severe | |
| 6 | 35 | M | 8 | Severe | |
| 7 | 58 | M | 5 | Severe | |
| 8 | 61 | F | 7 | Severe | |
| 9 | 33 | M | 8 | Severe | |
| 10 | 35 | F | 19 | Severe | |
| 11 | 21 | F | 4 | Severe | |
| 12 | 72 | F | 1 | Severe | |
| 13 | 36 | M | 15 | Moderate | |
| 14 | 42 | M | 7 | Severe | |
| 15 | 25 | F | 6 | Severe | |
| 16 | 51 | F | 18 | Severe | |
| 17 | 34 | M | 1 | Severe | |
| 1 | 68 | F | 15 | Severe | |
| 2 | 70 | F | 1 | Moderate | |
| 3 | 21 | F | 3 | Mild | |
| 4 | 54 | F | 20 | Moderate | |
| 5 | 52 | M | 20 | Mild | |
| 6 | 38 | M | 4 | Moderate | |
| 7 | 64 | M | 6 | Mild | |
| 8 | 38 | F | 16 | Severe | |
| 9 | 41 | F | 3 | Severe | |
| 10 | 57 | M | 10 | Mild |
CDAI: Crohn's Disease Activity Index; TWI: truelove-Witts index.
Frequency distribution for therapy
| No | 2 | 1 | 1 |
| Aminosalicydic acid | 9 | 8 | 1 |
| Cortisone | 2 | 2 | 0 |
| Aminosalicydic acid + Cortisone | 14 | 6 | 8 |
| Total | 27 | 17 | 10 |
Figure 2Panel a: Differences in baseline p-PIIIP values in Controls and IBD patients. Panel b: No significant differences in p-PIIIP values between CD and UC subgroups. Panel c: Differences between splancnic and periferic values of PIIIP, without significant differences in CD and UC sbgroups. p-PIIIP: periferic (median cubital vein) PIIIP; s-PIIIP: splancnic (mesenteric vein) PIIIP; Δ-PIIIP: differences between s- and p-PIIIP in IBD patients; IBD: inflammatory bowel diseases; CD: Crohn's Disease; UC: ulcerative colitis;
Baseline p-PIIIP levels in UC patients
| 7.05 ± 2.25 | |
| 3.9 ± 1.11 | |
| 3.13 ± 1.57* |
* p = 0.02 vs mild